- Home
- SKYE vs BSET Comparison
SKYE vs BSET Comparison
Compare SKYE & BSET Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SKYE
- BSET
- Stock Information
- Founded
- SKYE 2012
- BSET 1902
- Country
- SKYE United States
- BSET United States
- Employees
- SKYE N/A
- BSET N/A
- Industry
- SKYE Biotechnology: Pharmaceutical Preparations
- BSET Home Furnishings
- Sector
- SKYE Health Care
- BSET Consumer Discretionary
- Exchange
- SKYE Nasdaq
- BSET Nasdaq
- Market Cap
- SKYE 115.9M
- BSET 136.1M
- IPO Year
- SKYE N/A
- BSET 1987
- Fundamental
- Price
- SKYE $3.98
- BSET $18.28
- Analyst Decision
- SKYE Buy
- BSET
- Analyst Count
- SKYE 6
- BSET 0
- Target Price
- SKYE $16.60
- BSET N/A
- AVG Volume (30 Days)
- SKYE 2.2M
- BSET 93.2K
- Earning Date
- SKYE 08-08-2025
- BSET 07-09-2025
- Dividend Yield
- SKYE N/A
- BSET 4.40%
- EPS Growth
- SKYE N/A
- BSET N/A
- EPS
- SKYE N/A
- BSET 0.28
- Revenue
- SKYE N/A
- BSET $326,469,000.00
- Revenue This Year
- SKYE N/A
- BSET $2.22
- Revenue Next Year
- SKYE N/A
- BSET $3.28
- P/E Ratio
- SKYE N/A
- BSET $64.67
- Revenue Growth
- SKYE N/A
- BSET N/A
- 52 Week Low
- SKYE $1.14
- BSET $12.11
- 52 Week High
- SKYE $7.47
- BSET $19.75
- Technical
- Relative Strength Index (RSI)
- SKYE 60.88
- BSET 70.69
- Support Level
- SKYE $3.65
- BSET $15.73
- Resistance Level
- SKYE $4.75
- BSET $17.20
- Average True Range (ATR)
- SKYE 0.71
- BSET 0.90
- MACD
- SKYE 0.00
- BSET 0.42
- Stochastic Oscillator
- SKYE 48.55
- BSET 89.15
About SKYE Skye Bioscience Inc. Common Stock
Skye Bioscience Inc is a pre-clinical pharmaceutical company located in San Diego, California. The company's clinical assets focus on the modulation of cannabinoid receptor 1 ("CB1") to provide novel treatments and alternatives for diseases caused by metabolic disorders, inflammation, fibrosis, and neurodegeneration, such as obesity and glaucoma. The company's Phase 2 clinical candidates include nimacimab, a negative allosteric modulating antibody that inhibits peripheral CB1 receptors, currently being developed for the treatment of obesity and SBI-100 Ophthalmic Emulsion ("SBI-100 OE"), a CB1 agonist (activator), currently being developed for the treatment of glaucoma and ocular hypertension.
About BSET Bassett Furniture Industries Incorporated
Bassett Furniture Industries Inc is a manufacturer, marketer, and retailer of home furnishings products in the United States. It operates through the following segments: The Wholesale segment focuses on the design, manufacture, sourcing, sale, and distribution of furniture products, the Retail segment which consists of company-owned stores, and the Corporate and others segment. Majority of revenue is from Wholesale sales of furniture and accessories.